 John Carroll
Concepts (438)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 48 | 2022 | 136 | 14.050 |
Why?
| | Cardiac Catheterization | 56 | 2021 | 550 | 12.070 |
Why?
| | Foramen Ovale, Patent | 31 | 2021 | 39 | 11.730 |
Why?
| | Aortic Valve Stenosis | 41 | 2022 | 286 | 9.020 |
Why?
| | Coronary Angiography | 34 | 2020 | 334 | 7.420 |
Why?
| | Heart Valve Prosthesis Implantation | 23 | 2021 | 188 | 7.070 |
Why?
| | Septal Occluder Device | 21 | 2021 | 46 | 6.870 |
Why?
| | Echocardiography, Transesophageal | 18 | 2021 | 101 | 5.560 |
Why?
| | Echocardiography, Three-Dimensional | 12 | 2019 | 70 | 5.340 |
Why?
| | Heart Valve Prosthesis | 17 | 2021 | 130 | 4.870 |
Why?
| | Stroke | 29 | 2021 | 930 | 4.550 |
Why?
| | Heart Septal Defects, Atrial | 11 | 2020 | 57 | 4.270 |
Why?
| | Aortic Valve | 31 | 2022 | 449 | 4.230 |
Why?
| | Mitral Valve | 15 | 2021 | 107 | 4.100 |
Why?
| | Registries | 34 | 2022 | 1824 | 3.960 |
Why?
| | Imaging, Three-Dimensional | 25 | 2019 | 557 | 3.940 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 16 | 2019 | 118 | 3.690 |
Why?
| | Mitral Valve Insufficiency | 11 | 2021 | 65 | 3.670 |
Why?
| | Radiography, Interventional | 13 | 2020 | 101 | 3.670 |
Why?
| | Ultrasonography, Interventional | 11 | 2020 | 133 | 3.280 |
Why?
| | Heart Valve Diseases | 14 | 2019 | 179 | 3.210 |
Why?
| | Secondary Prevention | 12 | 2021 | 241 | 2.660 |
Why?
| | Echocardiography, Doppler, Color | 8 | 2019 | 45 | 2.500 |
Why?
| | Treatment Outcome | 70 | 2022 | 9002 | 2.480 |
Why?
| | Embolism, Paradoxical | 7 | 2020 | 7 | 2.160 |
Why?
| | Angioplasty, Balloon, Coronary | 13 | 2010 | 172 | 1.980 |
Why?
| | Fluoroscopy | 10 | 2021 | 137 | 1.930 |
Why?
| | Heart Defects, Congenital | 8 | 2020 | 711 | 1.920 |
Why?
| | Prosthesis Implantation | 6 | 2019 | 117 | 1.740 |
Why?
| | Cardiac Surgical Procedures | 7 | 2018 | 482 | 1.740 |
Why?
| | Humans | 184 | 2022 | 113846 | 1.700 |
Why?
| | Coronary Artery Disease | 11 | 2011 | 701 | 1.660 |
Why?
| | Stents | 17 | 2011 | 386 | 1.570 |
Why?
| | Thoracic Surgery | 10 | 2021 | 120 | 1.570 |
Why?
| | Heart Diseases | 5 | 2019 | 368 | 1.470 |
Why?
| | Catheterization | 8 | 2010 | 181 | 1.450 |
Why?
| | Heart Injuries | 4 | 2018 | 30 | 1.400 |
Why?
| | Coronary Vessels | 11 | 2010 | 283 | 1.400 |
Why?
| | Predictive Value of Tests | 20 | 2019 | 2025 | 1.390 |
Why?
| | Iatrogenic Disease | 3 | 2018 | 50 | 1.390 |
Why?
| | Cardiology | 12 | 2022 | 319 | 1.370 |
Why?
| | Cineangiography | 7 | 2009 | 21 | 1.350 |
Why?
| | Prostheses and Implants | 6 | 2013 | 157 | 1.340 |
Why?
| | Hypoxia | 4 | 2020 | 940 | 1.300 |
Why?
| | Image Enhancement | 3 | 2013 | 198 | 1.200 |
Why?
| | Radiation Dosage | 8 | 2016 | 144 | 1.180 |
Why?
| | Ischemic Attack, Transient | 3 | 2015 | 53 | 1.180 |
Why?
| | Mitral Valve Stenosis | 4 | 2016 | 26 | 1.170 |
Why?
| | Societies, Medical | 9 | 2020 | 768 | 1.170 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2015 | 725 | 1.160 |
Why?
| | Prosthesis Failure | 5 | 2020 | 118 | 1.150 |
Why?
| | Aged, 80 and over | 36 | 2022 | 6796 | 1.130 |
Why?
| | Coronary Stenosis | 4 | 2010 | 47 | 1.130 |
Why?
| | Prosthesis Design | 13 | 2019 | 242 | 1.130 |
Why?
| | Aged | 60 | 2022 | 20109 | 1.110 |
Why?
| | Male | 91 | 2021 | 60993 | 1.060 |
Why?
| | Sodium Chloride | 2 | 2015 | 173 | 1.040 |
Why?
| | Risk Factors | 36 | 2022 | 9050 | 1.040 |
Why?
| | Multimodal Imaging | 3 | 2020 | 110 | 0.980 |
Why?
| | Percutaneous Coronary Intervention | 2 | 2020 | 463 | 0.980 |
Why?
| | Platelet Aggregation Inhibitors | 9 | 2020 | 375 | 0.970 |
Why?
| | Contrast Media | 6 | 2015 | 414 | 0.970 |
Why?
| | Fibrinolytic Agents | 5 | 2021 | 244 | 0.960 |
Why?
| | Female | 83 | 2022 | 63035 | 0.940 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2380 | 0.930 |
Why?
| | Technology Transfer | 1 | 2021 | 15 | 0.920 |
Why?
| | United States | 39 | 2022 | 12329 | 0.900 |
Why?
| | Computed Tomography Angiography | 3 | 2020 | 67 | 0.870 |
Why?
| | Device Removal | 4 | 2012 | 122 | 0.850 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2021 | 1136 | 0.830 |
Why?
| | Embolism | 3 | 2019 | 43 | 0.830 |
Why?
| | Time Factors | 20 | 2022 | 7060 | 0.820 |
Why?
| | Migraine Disorders | 4 | 2021 | 70 | 0.800 |
Why?
| | Risk Assessment | 17 | 2021 | 3147 | 0.800 |
Why?
| | Surgery, Computer-Assisted | 4 | 2009 | 60 | 0.800 |
Why?
| | Coronary Occlusion | 1 | 2019 | 14 | 0.800 |
Why?
| | Postoperative Complications | 11 | 2021 | 2116 | 0.780 |
Why?
| | Mitral Valve Annuloplasty | 1 | 2019 | 5 | 0.780 |
Why?
| | Lacerations | 1 | 2019 | 28 | 0.780 |
Why?
| | Product Surveillance, Postmarketing | 4 | 2015 | 61 | 0.770 |
Why?
| | Echocardiography | 9 | 2020 | 637 | 0.770 |
Why?
| | Dyspnea | 1 | 2020 | 186 | 0.760 |
Why?
| | Technology Assessment, Biomedical | 2 | 2015 | 26 | 0.750 |
Why?
| | Shock, Cardiogenic | 1 | 2019 | 56 | 0.750 |
Why?
| | Balloon Occlusion | 3 | 2014 | 17 | 0.740 |
Why?
| | Surgeons | 4 | 2022 | 146 | 0.730 |
Why?
| | Middle Aged | 44 | 2021 | 28753 | 0.730 |
Why?
| | Thrombosis | 4 | 2012 | 265 | 0.730 |
Why?
| | Atrial Fibrillation | 4 | 2020 | 359 | 0.720 |
Why?
| | Radiographic Image Enhancement | 5 | 2009 | 68 | 0.710 |
Why?
| | Inferior Wall Myocardial Infarction | 1 | 2017 | 2 | 0.700 |
Why?
| | Heart Rupture, Post-Infarction | 1 | 2017 | 3 | 0.700 |
Why?
| | Papillary Muscles | 1 | 2017 | 18 | 0.690 |
Why?
| | Patient Selection | 10 | 2019 | 694 | 0.690 |
Why?
| | Models, Cardiovascular | 4 | 2008 | 185 | 0.680 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2017 | 42 | 0.660 |
Why?
| | Therapy, Computer-Assisted | 2 | 2014 | 60 | 0.650 |
Why?
| | Aortography | 1 | 2016 | 45 | 0.640 |
Why?
| | Multidetector Computed Tomography | 1 | 2016 | 29 | 0.630 |
Why?
| | Diagnostic Imaging | 3 | 2010 | 271 | 0.630 |
Why?
| | Aorta | 3 | 2009 | 410 | 0.630 |
Why?
| | Consensus | 9 | 2021 | 427 | 0.610 |
Why?
| | Echocardiography, Stress | 1 | 2015 | 28 | 0.610 |
Why?
| | Embolization, Therapeutic | 2 | 2007 | 95 | 0.610 |
Why?
| | Retrospective Studies | 22 | 2021 | 11340 | 0.610 |
Why?
| | Severity of Illness Index | 11 | 2021 | 2828 | 0.600 |
Why?
| | Exercise Test | 3 | 2015 | 598 | 0.600 |
Why?
| | Heart Ventricles | 3 | 2018 | 732 | 0.590 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 53 | 0.580 |
Why?
| | Heart Septal Defects, Ventricular | 3 | 2009 | 37 | 0.560 |
Why?
| | Foreign-Body Migration | 2 | 2012 | 34 | 0.560 |
Why?
| | Radiation Injuries | 1 | 2015 | 127 | 0.550 |
Why?
| | Reoperation | 6 | 2021 | 538 | 0.550 |
Why?
| | Heart Septal Defects | 3 | 2008 | 11 | 0.550 |
Why?
| | Health Policy | 1 | 2017 | 354 | 0.540 |
Why?
| | Balloon Valvuloplasty | 1 | 2013 | 4 | 0.530 |
Why?
| | Hospital Mortality | 11 | 2021 | 848 | 0.530 |
Why?
| | Surgical Instruments | 1 | 2012 | 45 | 0.490 |
Why?
| | Aortic Rupture | 1 | 2012 | 14 | 0.480 |
Why?
| | Incidence | 10 | 2021 | 2470 | 0.480 |
Why?
| | Reproducibility of Results | 13 | 2021 | 2905 | 0.480 |
Why?
| | Triiodobenzoic Acids | 2 | 2011 | 17 | 0.460 |
Why?
| | Coronary Disease | 5 | 2009 | 469 | 0.460 |
Why?
| | Models, Anatomic | 2 | 2009 | 103 | 0.450 |
Why?
| | Coronary Restenosis | 2 | 2009 | 22 | 0.450 |
Why?
| | Myocardial Infarction | 8 | 2008 | 1121 | 0.450 |
Why?
| | Adult | 28 | 2021 | 31979 | 0.440 |
Why?
| | Medicare | 6 | 2022 | 606 | 0.440 |
Why?
| | Catheter Ablation | 2 | 2018 | 316 | 0.440 |
Why?
| | Sensitivity and Specificity | 8 | 2019 | 1930 | 0.440 |
Why?
| | Algorithms | 9 | 2010 | 1558 | 0.430 |
Why?
| | Heart Atria | 5 | 2012 | 128 | 0.430 |
Why?
| | Prospective Studies | 14 | 2021 | 6250 | 0.430 |
Why?
| | Angiography | 4 | 2019 | 158 | 0.430 |
Why?
| | Computer Simulation | 5 | 2008 | 948 | 0.430 |
Why?
| | Equipment Design | 5 | 2014 | 531 | 0.410 |
Why?
| | Coronary Thrombosis | 1 | 2009 | 28 | 0.390 |
Why?
| | Angiocardiography | 1 | 2009 | 1 | 0.390 |
Why?
| | Follow-Up Studies | 14 | 2019 | 4906 | 0.380 |
Why?
| | Rotation | 4 | 2011 | 131 | 0.380 |
Why?
| | Anticoagulants | 4 | 2021 | 534 | 0.370 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 98 | 0.370 |
Why?
| | Clinical Decision-Making | 4 | 2019 | 274 | 0.370 |
Why?
| | Drug-Eluting Stents | 1 | 2009 | 71 | 0.370 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 728 | 0.370 |
Why?
| | Migraine with Aura | 1 | 2008 | 10 | 0.370 |
Why?
| | Heart Septum | 1 | 2008 | 32 | 0.360 |
Why?
| | Oxygen | 1 | 2013 | 892 | 0.360 |
Why?
| | Ventricular Septum | 1 | 2007 | 12 | 0.360 |
Why?
| | Stroke Volume | 2 | 2009 | 522 | 0.360 |
Why?
| | Survival Rate | 12 | 2021 | 1854 | 0.360 |
Why?
| | Monitoring, Intraoperative | 1 | 2007 | 37 | 0.360 |
Why?
| | Patient Simulation | 1 | 2008 | 35 | 0.350 |
Why?
| | Echocardiography, Doppler | 1 | 2008 | 128 | 0.350 |
Why?
| | Fistula | 1 | 2007 | 17 | 0.340 |
Why?
| | Pericardium | 1 | 2007 | 58 | 0.340 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1529 | 0.340 |
Why?
| | Coronary Artery Bypass | 1 | 2009 | 271 | 0.330 |
Why?
| | Catheters, Indwelling | 1 | 2007 | 90 | 0.330 |
Why?
| | Hemostatic Techniques | 1 | 2007 | 54 | 0.330 |
Why?
| | Comprehension | 1 | 2008 | 158 | 0.330 |
Why?
| | Health Status | 3 | 2021 | 773 | 0.330 |
Why?
| | Advisory Committees | 2 | 2018 | 204 | 0.330 |
Why?
| | Hemodynamics | 6 | 2020 | 1099 | 0.320 |
Why?
| | Blood Vessel Prosthesis | 2 | 2006 | 67 | 0.320 |
Why?
| | Wounds, Penetrating | 1 | 2007 | 81 | 0.320 |
Why?
| | Clinical Competence | 6 | 2019 | 913 | 0.320 |
Why?
| | Hemorrhage | 4 | 2018 | 577 | 0.320 |
Why?
| | Recurrence | 6 | 2021 | 967 | 0.310 |
Why?
| | Reconstructive Surgical Procedures | 1 | 2009 | 261 | 0.310 |
Why?
| | Aortic Diseases | 1 | 2007 | 99 | 0.310 |
Why?
| | Recovery of Function | 3 | 2019 | 604 | 0.310 |
Why?
| | Ischemia | 1 | 2009 | 314 | 0.310 |
Why?
| | Equipment Failure | 3 | 2012 | 130 | 0.310 |
Why?
| | Patient Readmission | 4 | 2019 | 621 | 0.300 |
Why?
| | Immunoglobulin Fab Fragments | 6 | 2008 | 69 | 0.300 |
Why?
| | Cohort Studies | 7 | 2021 | 5011 | 0.300 |
Why?
| | Aneurysm, False | 1 | 2005 | 38 | 0.300 |
Why?
| | N-Acetylmuramoyl-L-alanine Amidase | 1 | 2004 | 6 | 0.290 |
Why?
| | Ventricular Function, Left | 1 | 2009 | 489 | 0.290 |
Why?
| | Aortic Aneurysm | 1 | 2005 | 52 | 0.290 |
Why?
| | Equipment Safety | 1 | 2004 | 43 | 0.280 |
Why?
| | Education, Medical | 1 | 2008 | 244 | 0.280 |
Why?
| | Healthcare Disparities | 2 | 2020 | 465 | 0.280 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2004 | 25 | 0.270 |
Why?
| | Antiphospholipid Syndrome | 1 | 2004 | 26 | 0.270 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2003 | 12 | 0.260 |
Why?
| | Magnetic Resonance Angiography | 1 | 2005 | 220 | 0.250 |
Why?
| | Automation | 2 | 2016 | 75 | 0.250 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2006 | 388 | 0.250 |
Why?
| | Aspirin | 3 | 2020 | 317 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1214 | 0.240 |
Why?
| | Hospitals, High-Volume | 2 | 2019 | 46 | 0.240 |
Why?
| | Pacemaker, Artificial | 2 | 2020 | 116 | 0.240 |
Why?
| | Renal Insufficiency | 1 | 2003 | 124 | 0.240 |
Why?
| | Mycobacterium tuberculosis | 1 | 2004 | 251 | 0.230 |
Why?
| | Arteries | 1 | 2003 | 238 | 0.230 |
Why?
| | Decompression Sickness | 1 | 2021 | 4 | 0.230 |
Why?
| | Observer Variation | 4 | 2011 | 335 | 0.230 |
Why?
| | Prognosis | 5 | 2021 | 3544 | 0.230 |
Why?
| | Cost-Benefit Analysis | 3 | 2019 | 537 | 0.230 |
Why?
| | Learning Curve | 2 | 2019 | 65 | 0.220 |
Why?
| | Quality of Health Care | 3 | 2019 | 643 | 0.220 |
Why?
| | Health Resources | 2 | 2019 | 132 | 0.220 |
Why?
| | Cardiovascular Agents | 3 | 2014 | 127 | 0.220 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2014 | 140 | 0.210 |
Why?
| | Thromboembolism | 1 | 2021 | 104 | 0.210 |
Why?
| | American Heart Association | 2 | 2019 | 285 | 0.210 |
Why?
| | Length of Stay | 4 | 2020 | 1062 | 0.210 |
Why?
| | Databases, Factual | 3 | 2020 | 1206 | 0.200 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2015 | 252 | 0.200 |
Why?
| | Computer Systems | 2 | 2009 | 58 | 0.200 |
Why?
| | Colorado | 4 | 2019 | 4581 | 0.200 |
Why?
| | Rural Health Services | 1 | 2020 | 112 | 0.200 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2019 | 232 | 0.200 |
Why?
| | Hospitals, Low-Volume | 1 | 2019 | 27 | 0.190 |
Why?
| | Neurologists | 1 | 2019 | 16 | 0.190 |
Why?
| | Pattern Recognition, Automated | 3 | 2010 | 85 | 0.190 |
Why?
| | Popliteal Artery | 2 | 2009 | 49 | 0.190 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2019 | 67 | 0.190 |
Why?
| | Anatomic Landmarks | 1 | 2019 | 23 | 0.190 |
Why?
| | Comparative Effectiveness Research | 1 | 2020 | 143 | 0.190 |
Why?
| | Patient-Specific Modeling | 1 | 2019 | 35 | 0.190 |
Why?
| | Heart Valves | 1 | 2019 | 50 | 0.190 |
Why?
| | Atrioventricular Block | 1 | 2019 | 45 | 0.190 |
Why?
| | Treatment Failure | 3 | 2009 | 329 | 0.190 |
Why?
| | Cardiopulmonary Bypass | 1 | 2020 | 253 | 0.190 |
Why?
| | Hospital Costs | 1 | 2019 | 124 | 0.190 |
Why?
| | Angioplasty, Balloon | 2 | 2011 | 73 | 0.190 |
Why?
| | Antibodies, Monoclonal | 6 | 2008 | 1302 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 2 | 2007 | 3049 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2018 | 80 | 0.180 |
Why?
| | Bioprosthesis | 1 | 2018 | 42 | 0.180 |
Why?
| | Software | 2 | 2016 | 618 | 0.180 |
Why?
| | Young Adult | 6 | 2021 | 10971 | 0.180 |
Why?
| | Models, Organizational | 2 | 2019 | 159 | 0.180 |
Why?
| | Heart Block | 1 | 2018 | 51 | 0.180 |
Why?
| | Diagnostic Errors | 2 | 2010 | 158 | 0.180 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 1141 | 0.170 |
Why?
| | Intention to Treat Analysis | 2 | 2017 | 74 | 0.170 |
Why?
| | Risk | 3 | 2019 | 943 | 0.170 |
Why?
| | Coronary Circulation | 2 | 2007 | 171 | 0.170 |
Why?
| | Research Report | 1 | 2017 | 76 | 0.170 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 231 | 0.170 |
Why?
| | France | 1 | 2016 | 37 | 0.170 |
Why?
| | Disease Management | 2 | 2021 | 606 | 0.160 |
Why?
| | Single-Blind Method | 2 | 2017 | 280 | 0.160 |
Why?
| | Personal Satisfaction | 1 | 2018 | 173 | 0.160 |
Why?
| | Radiologic Health | 1 | 2015 | 5 | 0.160 |
Why?
| | Patient Safety | 2 | 2019 | 309 | 0.150 |
Why?
| | Atrial Pressure | 1 | 2015 | 2 | 0.150 |
Why?
| | Valsalva Maneuver | 1 | 2015 | 11 | 0.150 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 179 | 0.150 |
Why?
| | Radiation Exposure | 1 | 2016 | 46 | 0.150 |
Why?
| | Netherlands | 1 | 2015 | 70 | 0.150 |
Why?
| | Atrial Function, Right | 1 | 2015 | 16 | 0.150 |
Why?
| | Adolescent | 6 | 2021 | 18736 | 0.150 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2015 | 72 | 0.150 |
Why?
| | Movement | 2 | 2009 | 274 | 0.150 |
Why?
| | Heart Rate | 2 | 2011 | 844 | 0.140 |
Why?
| | Area Under Curve | 1 | 2015 | 328 | 0.140 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 385 | 0.140 |
Why?
| | Intersectoral Collaboration | 1 | 2015 | 60 | 0.140 |
Why?
| | Blood Vessel Prosthesis Implantation | 3 | 2004 | 101 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2019 | 441 | 0.140 |
Why?
| | Patient Care Team | 1 | 2019 | 532 | 0.140 |
Why?
| | Clinical Protocols | 1 | 2015 | 240 | 0.140 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2014 | 36 | 0.140 |
Why?
| | Cardiac Catheters | 1 | 2013 | 17 | 0.140 |
Why?
| | Multicenter Studies as Topic | 3 | 2022 | 222 | 0.130 |
Why?
| | Atrial Septum | 1 | 2013 | 4 | 0.130 |
Why?
| | ROC Curve | 1 | 2015 | 488 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2020 | 777 | 0.130 |
Why?
| | Punctures | 1 | 2013 | 40 | 0.130 |
Why?
| | X-Rays | 2 | 2010 | 29 | 0.130 |
Why?
| | Societies | 1 | 2013 | 39 | 0.130 |
Why?
| | Propensity Score | 3 | 2019 | 226 | 0.130 |
Why?
| | Global Health | 1 | 2016 | 339 | 0.130 |
Why?
| | Hospitals | 1 | 2017 | 468 | 0.130 |
Why?
| | Ultrasonography | 2 | 2008 | 773 | 0.130 |
Why?
| | Pancreaticoduodenectomy | 1 | 2014 | 136 | 0.120 |
Why?
| | Cardiovascular Diseases | 1 | 2004 | 1711 | 0.120 |
Why?
| | Femoral Artery | 2 | 2013 | 163 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2013 | 179 | 0.120 |
Why?
| | Research Design | 1 | 2018 | 913 | 0.120 |
Why?
| | Blood Pressure | 2 | 2011 | 1761 | 0.120 |
Why?
| | Forecasting | 2 | 2016 | 399 | 0.120 |
Why?
| | Phantoms, Imaging | 4 | 2010 | 137 | 0.120 |
Why?
| | Quality Improvement | 2 | 2019 | 934 | 0.110 |
Why?
| | Europe | 2 | 2009 | 351 | 0.110 |
Why?
| | Models, Statistical | 1 | 2016 | 693 | 0.110 |
Why?
| | Electrocardiography | 2 | 2014 | 661 | 0.110 |
Why?
| | Stress, Mechanical | 2 | 2003 | 473 | 0.110 |
Why?
| | Automation, Laboratory | 1 | 2010 | 9 | 0.110 |
Why?
| | Radiology, Interventional | 1 | 2010 | 25 | 0.100 |
Why?
| | Mitral Valve Prolapse | 1 | 2009 | 8 | 0.100 |
Why?
| | Data Collection | 1 | 2013 | 672 | 0.100 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 30 | 0.100 |
Why?
| | Heart | 1 | 2014 | 685 | 0.100 |
Why?
| | Hospitals, Veterans | 1 | 2011 | 277 | 0.100 |
Why?
| | Artificial Intelligence | 2 | 2010 | 90 | 0.100 |
Why?
| | Cause of Death | 3 | 2018 | 383 | 0.100 |
Why?
| | Artifacts | 2 | 2009 | 119 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 2 | 2021 | 211 | 0.100 |
Why?
| | Peripheral Vascular Diseases | 1 | 2009 | 95 | 0.100 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2009 | 40 | 0.100 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 133 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2019 | 5080 | 0.090 |
Why?
| | Nose | 1 | 2008 | 55 | 0.090 |
Why?
| | Robotics | 1 | 2009 | 78 | 0.090 |
Why?
| | Heart Failure | 2 | 2018 | 1899 | 0.090 |
Why?
| | Ticlopidine | 1 | 2008 | 69 | 0.090 |
Why?
| | Prevalence | 2 | 2018 | 2407 | 0.090 |
Why?
| | Leg | 1 | 2009 | 240 | 0.090 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2005 | 25 | 0.090 |
Why?
| | Endpoint Determination | 1 | 2008 | 69 | 0.090 |
Why?
| | Cardiac Tamponade | 1 | 2007 | 15 | 0.090 |
Why?
| | Motion | 2 | 2010 | 99 | 0.090 |
Why?
| | Sirolimus | 1 | 2009 | 182 | 0.090 |
Why?
| | Linear Models | 1 | 2010 | 909 | 0.090 |
Why?
| | Wakefulness | 1 | 2008 | 167 | 0.090 |
Why?
| | Quality of Life | 4 | 2021 | 2136 | 0.080 |
Why?
| | Injections | 1 | 2007 | 164 | 0.080 |
Why?
| | Quality Indicators, Health Care | 2 | 2019 | 307 | 0.080 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2006 | 100 | 0.080 |
Why?
| | Thoracotomy | 1 | 2006 | 89 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2008 | 1673 | 0.080 |
Why?
| | Age Factors | 2 | 2020 | 3330 | 0.080 |
Why?
| | Muramic Acids | 1 | 2004 | 1 | 0.070 |
Why?
| | Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2004 | 14 | 0.070 |
Why?
| | Peptidoglycan | 1 | 2004 | 23 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1079 | 0.070 |
Why?
| | Cell Wall | 1 | 2004 | 46 | 0.070 |
Why?
| | Ions | 1 | 2004 | 74 | 0.070 |
Why?
| | Feasibility Studies | 1 | 2007 | 739 | 0.070 |
Why?
| | Open Reading Frames | 1 | 2004 | 124 | 0.070 |
Why?
| | Whole-Body Irradiation | 1 | 2004 | 79 | 0.070 |
Why?
| | Probability | 1 | 2005 | 341 | 0.070 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2004 | 35 | 0.070 |
Why?
| | Genome, Bacterial | 1 | 2004 | 116 | 0.070 |
Why?
| | Informed Consent | 1 | 2005 | 156 | 0.070 |
Why?
| | Shear Strength | 1 | 2003 | 64 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2005 | 184 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2004 | 599 | 0.060 |
Why?
| | Thrombophilia | 1 | 2004 | 72 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 872 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1432 | 0.060 |
Why?
| | Patient Care Planning | 1 | 2003 | 166 | 0.060 |
Why?
| | Angioplasty | 1 | 2002 | 27 | 0.060 |
Why?
| | Elasticity | 1 | 2003 | 205 | 0.060 |
Why?
| | Diabetes Complications | 1 | 2005 | 249 | 0.060 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 9 | 0.060 |
Why?
| | Japan | 1 | 2022 | 95 | 0.060 |
Why?
| | Creatinine | 1 | 2003 | 461 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2052 | 0.060 |
Why?
| | Child | 2 | 2012 | 17711 | 0.060 |
Why?
| | Curriculum | 1 | 2008 | 818 | 0.060 |
Why?
| | Patient Discharge | 2 | 2004 | 743 | 0.050 |
Why?
| | Patient-Centered Care | 1 | 2006 | 477 | 0.050 |
Why?
| | Florida | 1 | 2020 | 80 | 0.050 |
Why?
| | Acute Disease | 1 | 2003 | 1000 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1004 | 0.050 |
Why?
| | Escherichia coli | 1 | 2004 | 812 | 0.050 |
Why?
| | Syndrome | 1 | 2021 | 347 | 0.050 |
Why?
| | Population Density | 1 | 2020 | 96 | 0.050 |
Why?
| | Base Sequence | 1 | 2004 | 2321 | 0.050 |
Why?
| | Norepinephrine | 1 | 2001 | 276 | 0.050 |
Why?
| | Travel | 1 | 2020 | 106 | 0.050 |
Why?
| | Computational Biology | 1 | 2004 | 674 | 0.050 |
Why?
| | Epinephrine | 1 | 2001 | 191 | 0.050 |
Why?
| | Cardiac Care Facilities | 1 | 2019 | 15 | 0.050 |
Why?
| | Cost Savings | 1 | 2019 | 83 | 0.050 |
Why?
| | Decision Making | 1 | 2006 | 774 | 0.050 |
Why?
| | Cardiac Imaging Techniques | 1 | 2019 | 20 | 0.050 |
Why?
| | Credentialing | 1 | 2019 | 13 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 3118 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2021 | 580 | 0.050 |
Why?
| | Trauma Severity Indices | 1 | 2019 | 143 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2020 | 229 | 0.050 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.050 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2019 | 93 | 0.050 |
Why?
| | Inpatients | 2 | 2016 | 335 | 0.050 |
Why?
| | Renin-Angiotensin System | 1 | 2018 | 88 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2020 | 281 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 368 | 0.040 |
Why?
| | Workload | 1 | 2019 | 134 | 0.040 |
Why?
| | Risk Management | 1 | 2018 | 96 | 0.040 |
Why?
| | Markov Chains | 1 | 2018 | 127 | 0.040 |
Why?
| | Child, Preschool | 1 | 2012 | 9717 | 0.040 |
Why?
| | United Kingdom | 1 | 2018 | 246 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 877 | 0.040 |
Why?
| | Intraoperative Complications | 1 | 2018 | 125 | 0.040 |
Why?
| | Altitude | 1 | 2001 | 467 | 0.040 |
Why?
| | Mortality | 1 | 2018 | 328 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 368 | 0.040 |
Why?
| | Biomarkers | 1 | 2006 | 3501 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2019 | 329 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2016 | 209 | 0.040 |
Why?
| | Medicaid | 1 | 2018 | 373 | 0.040 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 179 | 0.040 |
Why?
| | Survival Analysis | 1 | 2018 | 1414 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2019 | 610 | 0.040 |
Why?
| | Karnofsky Performance Status | 1 | 2014 | 38 | 0.030 |
Why?
| | Duodenal Neoplasms | 1 | 2014 | 11 | 0.030 |
Why?
| | Spatio-Temporal Analysis | 1 | 2014 | 34 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1601 | 0.030 |
Why?
| | Bile Duct Neoplasms | 1 | 2014 | 58 | 0.030 |
Why?
| | Radiation | 1 | 2013 | 26 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 2053 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 176 | 0.030 |
Why?
| | Torsion, Mechanical | 1 | 2009 | 8 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2005 | 1243 | 0.030 |
Why?
| | Laparoscopy | 1 | 2014 | 383 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 127 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 602 | 0.020 |
Why?
| | Exercise | 1 | 2001 | 1718 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 138 | 0.020 |
Why?
| | Posture | 1 | 2009 | 192 | 0.020 |
Why?
| | Radiography | 1 | 2010 | 828 | 0.020 |
Why?
| | Vascular Surgical Procedures | 1 | 2009 | 232 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2009 | 669 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 744 | 0.020 |
Why?
| | Myocardial Ischemia | 1 | 2008 | 309 | 0.020 |
Why?
| | Platelet Count | 1 | 2005 | 92 | 0.020 |
Why?
| | Age Distribution | 1 | 2005 | 403 | 0.020 |
Why?
| | Sex Distribution | 1 | 2005 | 395 | 0.020 |
Why?
| | Patient Admission | 1 | 2004 | 198 | 0.020 |
Why?
| | Odds Ratio | 1 | 2005 | 1064 | 0.010 |
Why?
| | Myocardial Reperfusion | 1 | 2002 | 75 | 0.010 |
Why?
| | Heparin | 1 | 2003 | 221 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2003 | 484 | 0.010 |
Why?
| | Postoperative Care | 1 | 2003 | 233 | 0.010 |
Why?
| | Prazosin | 1 | 2001 | 38 | 0.010 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2001 | 42 | 0.010 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 42 | 0.010 |
Why?
| | Phenylephrine | 1 | 2001 | 114 | 0.010 |
Why?
| | Health Care Costs | 1 | 2003 | 395 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2001 | 664 | 0.010 |
Why?
|
|
Carroll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|